| 1 |
Garnacho-Montero J, Barrero-García I, Gómez-Prieto MG, et al. Severe community-acquired pneumonia: current management and future therapeutic alternatives[J]. Expert Rev Anti Infect Ther, 2018, 16 (9): 667-677.
|
| 2 |
Tanzella G, Motos A, Battaglini D, et al. Optimal approaches to preventing severe community-acquired pneumonia[J]. Expert Rev Respir Med, 2019, 13 (10): 1005-1018.
|
| 3 |
Wang J, Song YL. Advances in severe community-acquired pneumonia[J]. Chin Med J (Engl), 2019, 132 (16): 1891-1893.
|
| 4 |
Siow WT, Koay ES, Lee CK, et al. The use of polymerase chain reaction amplification for the detection of viruses and bacteria in severe community-acquired pneumonia[J]. Respiration, 2016, 92 (5): 286-294.
|
| 5 |
Sun T, Wu X, Cai Y, et al. Metagenomic next-generation sequencing for pathogenic diagnosis and antibiotic management of severe community-acquired pneumonia in immunocompromised adults[J]. Front Cell Infect Microbiol, 2021 (11): 661589.
|
| 6 |
李学青，王丽娜，张俐，等.肺泡灌洗液二代基因测序对儿童重症肺炎病原学诊断应用观察[J].中国实用儿科杂志，2019，34（6）：513-516.
|
| 7 |
Miao Q, Ma Y, Wang Q, et al. Microbiological diagnostic performance of metagenomic next-generation sequencing when applied to clinical practice[J]. Clin Infect Dis, 2018, 67 (suppl_2): S231-S240.
|
| 8 |
中华医学会呼吸病学分会.中国成人社区获得性肺炎诊断和治疗指南（2016年版）[J].中华结核和呼吸杂志，2016，39（4）：253-279.
|
| 9 |
Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009[J]. Thorax, 2009 (64 Suppl 3): iii1-iii55.
|
| 10 |
徐凯峰，陈勇.纤维支气管镜临床应用的适应证和注意事项[J].中国全科医学，2008，11（4）：281-283.
|
| 11 |
杨国彪，孙小军，徐萌敏.纤维支气管镜肺泡灌洗联合振动排痰在重症肺炎机械通气患者中的应用[J/CD].中华危重症医学杂志（电子版），2020，13（2）：138-140.
|
| 12 |
Rider AC, Frazee BW. Severe community-acquired pneumonia[J]. Emerg Med Clin North Am, 2018, 36 (4): 665-683.
|
| 13 |
Liu Y, Zhang C, Li C, et al. Marked reduction in 28-day mortality among elderly patients with severe community-acquired pneumonia: post hoc analysis of a large randomized controlled trial[J]. Clin Interv Aging, 2020 (15): 2109-2115.
|
| 14 |
Du S, Wu X, Li B, et al. Clinical factors associated with composition of lung microbiota and important taxa predicting clinical prognosis in patients with severe community-acquired pneumonia[J]. Front Med, 2022,16 (3): 389-402.
|
| 15 |
Phua J, Dean NC, Guo Q, et al. Severe community-acquired pneumonia: timely management measures in the first 24 hours[J]. Crit Care, 2016, 20 (1): 237.
|
| 16 |
林明珍，赵磊.宏基因组的二代测序技术在初治失败社区获得性肺炎患者病原菌检测中的应用价值[J].临床肺科杂志，2021，26（8）：1180-1184.
|
| 17 |
Shi J, Sun T, Cui Y, et al. Multidrug resistant and extensively drug resistant Acinetobacter baumannii hospital infection associated with high mortality: a retrospective study in the pediatric intensive care unit[J]. BMC Infect Dis, 2020, 20 (1): 597.
|
| 18 |
Boral B, Unaldi O, Ergin A, et al. A prospective multicenter study on the evaluation of antimicrobial resistance and molecular epidemiology of multidrug-resistant Acinetobacter baumannii infections in intensive care units with clinical and environmental features[J]. Ann Clin Microbiol Antimicrob, 2019, 18 (1): 19.
|
| 19 |
梁虹艺，叶嘉盛，万宁，等.真实世界中国产与进口替加环素治疗泛耐药鲍曼不动杆菌感染的有效性、安全性、经济性研究[J].中国新药与临床杂志，2022，41（1）：28-33.
|
| 20 |
Sando E, Suzuki M, Ishida M, et al. Definitive and indeterminate Pseudomonas aeruginosa infection in adults with community-acquired pneumonia: a prospective observational study[J]. Ann Am Thorac Soc, 2021, 18 (9): 1475-1481.
|
| 21 |
Cillóniz C, Gabarrús A, Ferrer M, et al. Community-acquired pneumonia due to multidrug- and non-multidrug-resistant pseudomonas aeruginosa[J]. Chest, 2016, 150 (2): 415-425.
|
| 22 |
Paganin F, Lilienthal F, Bourdin A, et al. Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor[J]. Eur Respir J, 2004, 24 (5): 779-785.
|
| 23 |
王艳红，石云锋，罗进梅，等.社区来源肺炎克雷伯菌性脓毒性休克10例分析[J/CD].中华危重症医学杂志（电子版），2020，13（5）：370-372.
|
| 24 |
马艳良.肺部曲霉菌感染的诊断与治疗[J].临床内科杂志，2020，37（10）：689-692.
|
| 25 |
王晓丹.病毒性肺炎诊治进展[J].医学理论与实践，2020，33（2）：204-206.
|